Sends email in progress
 
Scientific news
Has the prothrombotic mechanism of the JAK-2 V617F mutation finally been solved?
Reviewed Article
Published online: Monday, November 23, 2015
Has the prothrombotic mechanism of the JAK-2 V617F mutation finally been solved?
par Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
Patients with polycythaemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF) are at an increased risk of arterial and venous thrombosis compared with patients with chronic myeloid leukemia (CML).
In patients with ET, a positive correlation was observed between JAK-2 V617F mutation (which facilitates erythropoietin receptor signalling) and
Read more
How are elderly subjects with Parkinson's disease and diabetes managed?
Syndromes parkinsoniens
Reviewed Article
Published online: Wednesday, November 18, 2015
How are elderly subjects with Parkinson's disease and diabetes managed?
par Dr Raja Moukhlis (Paris)
Elderly type 2 diabetic (T2DM) patients have many comorbidities that can affect their overall prognosis. Therefore, the analysis of comorbidities is of major importance.
This study evaluated the management of diabetes in elderly patients with Parkinson's disease and how their prognosis is affected.
Read more
Tinzaparin allows to reduce cisplatin resistance of ovarian cancer cells
Reviewed Article
Published online: Thursday, September 17, 2015
Tinzaparin allows to reduce cisplatin resistance of ovarian cancer cells
par Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
Low molecular weight heparins (LMWH) are commonly used in prevention and treatment of thrombosis in cancer patients. An anti-metastatic effect has also been discussed and could increase survival in patients, regardless of antithrombotic effects.
The objective of this study was to understand the potential interactions between LMWH treatment and treatment of ovarian cancer with cisplatin...
Read more
Dosage plasmatique du VEGF : vers un nouveau biomarqueur de thrombose chez les patients cancéreux ?
Reviewed Article
Published online: Thursday, September 17, 2015
Dosage plasmatique du VEGF : vers un nouveau biomarqueur de thrombose chez...
par Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
Predictive factors for venous thromboembolism (VTE) and their recurrence in patients with cancer are poorly understood. Thus, the research for biomarkers of deep vein thrombosis (DVT) would identify high risk patients and potentially adapt anticoagulant therapy.
Since the early 1990s, the angiogenic switch, i.e. the transition of tumours to the metastatic stage, has been attributed to peritumoral vascular growth and particularly to the main
Read more
Endothelial cellular and plasma biomarkers before surgery do not predict the prognosis of colorectal cancers
Reviewed Article
Published online: Thursday, September 17, 2015
Endothelial cellular and plasma biomarkers before surgery do not predict the...
par Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
Tumour vasculature and broadly speaking, actors in angiogenesis are therapeutic targets in cancer. The response to treatment could be assessed by circulating cellular biomarkers, circulating endothelial cells (CEC) or endothelial progenitor cells (EPC).
CECs may reflect the active remodelling...
Read more
What is the role of endothelial differentiation of cancer cells in the development of tumour vasculature and the response to antiangiogenic treatments?
Reviewed Article
Published online: Tuesday, June 23, 2015
What is the role of endothelial differentiation of cancer cells in the...
par Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
The differentiation of tumour cells into endothelial cells in situ has been proposed in glioblastoma, but this process is still largely unexplored. The relevance of this transdifferentiation as well as the role of VEGF and its receptors remains to be elucidated. Moreover, this phenomenon has only been reported in glioblastomas.
Read more
All scientific articles
The daily press review of medical news and health